In this medfyle

A recent study evaluated the CLL-IPI in patients treated first-line with either targeted drugs or chemoimmunotherapy. With a median observation time of over 40 months, the study found that targeted therapies resulted in higher 3-year PFS rates across all CLL-IPI risk groups compared to chemoimmunotherapy. However, while the CLL-IPI maintained its predictive power for PFS outcomes, its impact on OS was less pronounced. These findings underscore the effectiveness of targeted therapies and support the continued evaluation of prognostic tools in CLL treatment.